NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $3 | $6 | $6 |
| - Cash | $13 | $15 | $14 | $17 |
| + Debt | $5 | $5 | $6 | $6 |
| Enterprise Value | -$7 | -$6 | -$2 | -$5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$3 | -$4 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$3 | -$4 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -660.26 | -2.04 | -2.4 | -3.04 |
| % Growth | -32,265.7% | 15% | 21.1% | – |
| Operating Cash Flow | -$2 | -$4 | -$3 | -$6 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$4 | -$3 | -$6 |